Kornimate/medical-research-clean huggingface dataset:
characterization of sweat gland function in patients with recessively inherited hypohidrotic ectodermal dysplasia

Conditions: Hypohidrotic Ectodermal Dysplasia

Summary: hypohidrotic ectodermal dysplasia (hed) is a complex genetic disorder characterized by lack of sweat glands, sparse hair, and missing or malformed teeth. inability to sweat may result in episodes of severe hyperthermia and cause sudden infant death. to assess sweat gland function in hed patients, the investigators will first quantify gland pores in a defined area of the palm and then stimulate the glands by pilocarpine followed by sweat collection in a special capillary for volume determination. this will be combined with non-invasive skin conductance measurement prior and subsequent to stimulation of the sympathetic nervous system. the data should provide a basis for genotype-phenotype correlation.


Eligibility criteria:
inclusion criteria: * for patients: hypohidrotic ectodermal dysplasia caused by mutations in the genes eda or edar * written informed consent exclusion criteria: * febrile disease * pregnancy or breastfeeding * implantable electronic devices, e.g. pacemaker * hypersensitivity to self-adhesive electrodes
a study to evaluate a leukapheresis treatment in patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to determine whether a treatment of a novel leukapheresis column is safe and effective in patients with moderate to severe ulcerative colitis.

ulcerative colitis (uc) is a chronic and relapsing disease and is characterized by superficial inflammation in the colonic epithelium. the inflammation is maintained by continuous supply of inflammatory cells from the circulating blood to the intestinal mucosa. existing therapy e.g. corticosteroids and immunosuppressants are inadequate with an overall long-term remission rate of only 50-60%. those treatments are also associated with severe side effects why there is a need of new therapies. the aim of this study is to investigate a novel leukapheresis treatment with the potential to reduce the number of inflammatory cells homing to the gut mucosa. by drawing blood from the patient and pass it through the investigational column the inflammatory cells are removed. the blood, depleted of the inflammatory cells, is returned to the patient. the treatment thus enable down-regulation of the inflammation and consequently the inflammation can heal. the treatment is called tailored leukapheresis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of active, moderate-to-severe, ulcerative colitis. exclusion criteria; * local intestinal treatments with suppositories, enemas or clysmas during the last 4 weeks * current daily smoking habits * other severe diseases as detailed in the protocol * history of hypersensitivity to heparin

Keywords: ulcerative colitis leukapheresis treatment
v4 study evaluating the safety, tolerability and preliminary pharmacokinetics and pharmacodynamics of myk-491

Conditions: Heart Failure With Reduced Ejection Fraction; Dilated Cardiomyopathy

Summary: the purpose of this phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of myk-491 in patients with stable heart failure.


Eligibility criteria:
key inclusion criteria: * has stable chronic heart failure with reduced ejection fraction * has adequate acoustic windows for echocardiography key exclusion criteria: * any significant structural cardiac abnormalities on screening tte * at screening, symptomatic hypotension or hypertension or bradycardia. * routinely scheduled outpatient intravenous (iv) infusions for heart failure (e.g., inotropes, vasodilators \[e.g., nesiritide\], diuretics) or routinely scheduled ultrafiltration. * presence of protocol specified laboratory abnormalities at screening.
drug-eluting balloon for treatment of non-atherosclerotic renal artery stenosis--a multicenter study

Conditions: Hypertension, Renovascular

Summary: the study will test the efficacy of drug eluting balloon(deb) for non-atherosclerotic renal artery stenosis. the deb (paclitaxel eluting balloon) will be used in the intervention group, while the plain old balloon(pob) will be used in the control group. the primary outcome is the effect of blood pressure control.


Eligibility criteria:
inclusion criteria: * age between 18y and 45y. * with ≥ 60% stenosis in at least one renal artery. * with hypertension (systolic blood pressure ≥140 mmhg or diastolic blood pressure ≥ 90 mmhg). * patients with no severe renal insufficiency (egfr\>30 ml/min, length of the kidney ≥ 7cm). * good compliance. * with informed consent. exclusion criteria: * with apparent atherosclerotic risk factors. * with renal intervention or surgery history. * with congenital anatomical anomaly. * with severe renal insufficiency (length of the target kidney \< 7cm, total * egfr\<30ml/min, divided egfr of the target kidney\<8 ml/min) * with contraindication for antiplatelet therapy. * with severe cardiopulmonary insufficiency. * allergic to contrast medium * being pregnant or preparing for pregnancy * with active cancer. * life expectancy \< 12 month * without informed consent
takecharge: telephone delivered self-management intervention for people with multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: the proposed project will evaluate the efficacy of a telephone-delivered self-management (t-sm) intervention for reducing the impact of secondary conditions in persons with multiple sclerosis (ms), including chronic pain, fatigue, depression, and cognitive impairment. it is hypothesized that if the effects of these conditions are reduced, study participants will demonstrate improved participation in the community and improved employment outcomes. this project is important because the majority of persons with ms experience one or more of the following secondary conditions: fatigue, pain, depression, and cognitive impairment. these secondary conditions are not always readily apparent and constitute what has been described by our rehabilitation research and training center as "hidden disabilities." secondary conditions such as pain, depression, fatigue, and cognitive impairment frequently not only cause distress in their own right but also affect employment, participation, and quality of life. having more than one often compounds the effect; the effect of all may be greater than the sum of each individually (e.g. depression can worsen fatigue, and cognitive impairment can worsen depression). it is critical that this constellation of secondary symptoms be addressed using state of the art techniques based on self-management training and that intervention effects be documented with carefully controlled treatment efficacy studies.


Eligibility criteria:
inclusion criteria: * must be diagnosed with ms by a physician. * must be at least 18 years of age. * must be able to understand, speak, and read english. * must have the presence of at least one of four common secondary conditions (fatigue, pain, depression, cognitive difficulties) that interferes with employment, participation, and functioning. exclusion criteria: * unable to understand or read english. * severe cognitive impairment, defined as one or more errors on the 6-item screener, that would prevent informed consent and inability to carry on a phone conversation. * currently participating in regularly scheduled psychotherapy. * psychiatric contraindications such as current psychosis, active suicidal ideation, or current alcohol or drug use.

Keywords: pain fatigue depression cognitive difficulties self-management
percutaneous laparoscopy for ovarian tissue cryopreservation.

Conditions: Oncology; Fertility Issues; Surgery

Summary: to compare surgical outcomes of oncologic patients that underwent conventional laparoscopy and percutaneous laparoscopy for cryopreservation of ovarian tissue.

this is a retrospective analysis to evaluate the efficacy and safety of percutaneous laparoscopy for the ovarian tissue explant in oncologic women. surgical outcomes of patients that underwent percutaneous laparoscopy were compared with those of women that underwent conventional laparoscopy. data from 2017 to 2021 were collected in a single oncologic center in italy. the principal outcomes considered are post-operative pain, recovery time and aesthetic outcomes.

Eligibility criteria:
inclusion criteria: * oncologic women with desire to preserve fertility exclusion criteria: * ovarian explant with different techniques than laparoscopy

Keywords: percuvataneous laparoscopy ovarian tissue cryopreservation
group b streptococcal carrier state prevalence among arab pregnant women in northern israel district

Conditions: Streptococcus B Carrier State Complicating Pregnancy

Summary: the incidence of early neonatal gbs (group b streptococcus) infection in the nazareth hospital through the years 2006-2013 has been higher compared to the national average. on reviewing all the cases of infants with early gbs infection, revealed that some of these infants were born to mothers who are not included in any of the high-risk groups that need to have prophylactic antibiotic treatment before delivery. therefore, the question was whether pregnant arab women in the north district of israel have a higher gbs carrier state rate than the general rate in israel?

signs of early onset gbs infection of the newborn appear during the first week of life. usually, the bacteria pass from a gbs carrier mother to the newborn during labor. the infection can cause multi-system problems such as pneumonia, meningitis and even death of the newborn. the prevention of the disease is best achieved by prophylactic antibiotics administered to the mother during labor. in order to prevent early onset gbs infection of the newborn, pregnant women are treated with preventive antibiotics during labor based on either of two protocols: a. risk factors: women with risk factors such as premature birth, prolonged premature rupture of membranes, intra-partum maternal fever or a previous child with gbs infection are treated. b. universal screening: towards the end of pregnancy, at 35 - 37th week, a vaginal/anal swab for gbs is taken, and those found positive will be treated. according to the israeli ministry of health regulations' from july 2005 it is not accepted to routinely perform screening for gbs in pregnant women at 35-37th week of pregnancy. therefore, the israeli approach to prevent early neonatal gbs infection is based mainly on antibiotic prophylaxis treatment during labor of all pregnant women with risk factors. in a study conducted at the western galilee medical center in the city of nahariya and published in 2006, there was a significant increase in the gbs carrier state rate compared to previously published studies. it was also found that higher gbs carrier state rates prevail among arab women compared to jewish women. the primary question of this study is to calculate gbs carrier state prevalence among pregnant arab women attending the labor ward at the nazareth hospital at the 34 to 40th week of their pregnancy. a vaginal / anal swab will be taken from all eligible participants to identify gbs carriers by pcr (polymerase chain reaction) test.

Eligibility criteria:
inclusion criteria: 1. age: 18 to 40 2. origin: arab 3. gestational age: 34 to 40 exclusion criteria: 1. rupture of membranes 2. women in active labor who has had one or more vaginal examinations.

Keywords: group b streptococcus gbs
long-term stability and survival rates of a novel oticon medical bone conduction device implant

Conditions: Deafness; Hearing Loss; Hearing Loss, Conductive; Hearing Disorders; Ear Diseases; Otorhinolaryngologic Diseases

Summary: the overall aim of the study is to investigate the ponto wide implant considering; initial implant stability, stability over time, skin reaction and long term success when loaded at 3 weeks post surgery. patients' quality of life improvements following implantation will also be surveyed. more specifically the primary objective of this clinical study is to test the hypothesis * the new ponto wide diameter implant offers increased implant stability measured as isq (implant stability quotient) compared to the previous generation ponto implant. and the secondary objective is to * investigate when in time implant stability is the lowest as the initial mechanical stability is gradually replaced by biological stability


Eligibility criteria:
inclusion criteria: * 18 years or older * patient indicated for an ear level bone anchored sound processor * bone thickness at the implant site of at least 4 mm exclusion criteria: * longer abutment (\>6mm) required * inability to participate in follow-up * psychiatric disease in the medical history * mental disability * presumed doubt, for any reason, that the patient will be able to show up on all follow ups * diseases or treatments known to compromise the bone quality at the implant site, e.g. radiotherapy, osteoporosis, diabetes mellitus.

Keywords: bone anchored hearing aid bone anchored implant implant stability wide diameter implant linear incision ponto
intravenous tranexamic acid and intramyometrial desmopressin effect on blood loss during laparoscopic myomectomy.

Conditions: Leiomyoma, Uterine; Intraoperative Blood Loss

Summary: to evaluate the effect of intravenous tranexamic acid plus intramyometrial desmopressin administration on perioperative blood loss and blood transfusion need in laparoscopic myomectomy operation.

although complication rates such as bleeding are observed to be low in surgeries performed by experienced surgeons, sometimes severe bleeding that may require emergency blood transfusion can be encountered during myomectomy operation. therefore, various medical treatments such as vasopressin, misoprostol, ascorbic acid are still being sought to reduce the amount of intraoperative bleeding. tranexamic acid is a lysine-derived drug with an antifibrinolytic effect, which has been used for a long time, especially in orthopedic and cardiovascular surgeries, to stop bleeding and reduce the need for blood transfusions, and is often well tolerated and has few side effects. it has a good safety profile with the food and drug administration (fda) pregnancy category b and is a drug frequently used in postpartum hemorrhage. it is also used to reduce bleeding in bleeding observed in many gynecological surgeries such as hypermenorrhea, bleeding in intrauterine device application and cervical conization. in the investigator's clinic, intramyometrial desmopressin administration is routinely used in most cases. although the application of various intraoperative medical treatments in laparoscopic myomectomies has been examined in the literature, there are not enough prospective studies investigating the administration of desmopressin and intravenous tranexamic acid. in the investigator's study, investigators plan to evaluate the effect of the combined use of these two drugs on intraoperative bleeding and the need for blood transfusion compared to placebo.

Eligibility criteria:
inclusion criteria: * healthy volunteer female patients over the age of 18 who will undergo laparoscopic myomectomy in our clinic will be included in our study. exclusion criteria: 1. patients who are planned to undergo different surgery along with myomectomy 2. those with a diagnosis and suspicion of malignancy 3. those with a history of thromboembolic disease 4. those with cardiac, hepatic or renal disease 5. those with a body mass index of 30 and above 6. patients with abnormal coagulation test results 7. patients using anticoagulants 8. those who use drugs or diseases that may affect coagulation (serum creatinine \> 1.5 mg/dl) 9. those allergic to tranexamic acid

Keywords: leiomyoma laparoscopic myomectomy tranexamic acid blood loss i̇ntramyometrial desmopressin
a post marketing safety study of sitagliptin (januvia®) (mk-0431-234)

Conditions: Diabetes Mellitus, Type 2

Summary: the primary objective of this study is to obtain safety information on the use of sitagliptin (januvia®) from endocrinologists, diabetologists, internists, and general practitioners.


Eligibility criteria:
inclusion criteria: - must be taking sitagliptin (januvia™) for the treatment of type 2 diabetes mellitus - treating physician must agree to provide information regarding the participants treatment
mitomycin c trabeculectomy trial for glaucoma in ethiopia

Conditions: Glaucoma

Summary: this study is a randomized, double-masked trial to examine the response to trabeculectomy surgery. in this study, patients will be randomized to receive mmc via subconjunctival injection or topical sponge application.

this study is a randomized, double-masked (study participants and outcome assessors) trial. during the enrollment period, patients from menelik hospital who are planning to have trabeculectomy surgery and who meet the study enrollment criteria will be randomized to receive mitomycin c applied topically or by injection during the surgery.at menelik hospital mitomycin-c (mmc) is routinely applied to the eye prior to trabeculectomy by physicians via both sponge and injection routes. the primary outcome is the patient's response to the trabeculectomy procedure, as measured by cumulative complications after a 3-month follow-up period post-operation. secondary outcome is the change in intraocular pressure after a 3 month follow-up period. the investigators will perform subgroup analyses by stratifying the population according to skin pigmentation to determine whether pigmentation is a predictor of treatment success.

Eligibility criteria:
inclusion criteria: * age \>=40 * planning to have a trabeculectomy exclusion criteria: * life threatening or debilitating disease * inability to complete necessary exams and/or ocular disease that would preclude assessment of intraocular pressure, visual field, or optic disc * pseudophakic lens * contralateral eye already enrolled in study

Keywords: eye disease intraocular pressure visual acuity trabeculectomy
triage liaison physician - evaluation of a novel approach to address emergency department overcrowding

Conditions: Acute Illness

Summary: this randomized controlled trial will introduce a triage liaison physician (tlp) into the university of alberta hospital emergency department (ed) and assess the influence on patients who leave without being seen, ed length of stay, and other ed overcrowding outcomes.

ed overcrowding is a significant cause of delayed care, patient dissatisfaction, and poor outcomes in north american eds. this intervention has not been widely studied; however, it represents an opportunity for improving patient flows in eds.

Eligibility criteria:
inclusion criteria: * only adult patients (\> 17 years of age) presenting to the university of alberta hospital emergency department (uah ed), during the study interval will be included in the evaluation. exclusion criteria: * direct admits/pediatric patients.

Keywords: ed overcrowding length of stay emergency triage triage
anorexia nervosa inpatient physiotherapy adapted program

Conditions: Anorexia Nervosa

Summary: anorexia nervosa (an) is a psychiatric pathology with several somatics consequences that increase the vital risk. the prevalence in an is between 0.9-3% and an has the most elevated mortality in the psychiatric pathologies (10% in the hospitalized patients). the collateral effects by several undernourishment has been studied but the autonomy and muscle strength research is insufficient. physiotherapy research study body image, basic body awareness therapy, relaxation and quality of life.

objetive: develop a physiotherapy program to increase muscle strength and quality of life in anorexia nervosa hospitalized patients. method: 4 weeks of adapted exercises (3 days/week) in anorexia nervosa patients with body max index under 16 in interventional group. and evaluation program once a week in interventional group and control group.

Eligibility criteria:
inclusion criteria: * women * hospitalized * anorexia nervosa * body mass index (kg/m2) \< 16 exclusion criteria: * men

Keywords: anorexia nervosa muscle strength peak-expiratory-flow quality of life
pharmacokinetics and pharmacodynamics of lapatinib in two dosing regimens in treatment-naive patients with breast cancer

Conditions: Neoplasms, Breast

Summary: this study will examine the inhibition of erbb1 and erbb2 phosphorylation and downstream mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer patients for three dosing schedules of lapatinib.


Eligibility criteria:
inclusion criteria: * clinical labs are within acceptable ranges. * a histologically confirmed, treatment-naive, breast tumor measuring 1 cm or greater that can be readily biopsied. * at least 18 years of age. * females must meet certain criteria specified in protocol. * ability to swallow and retain oral medication. * ability to follow and understand directions. exclusion criteria: * female who is pregnant or lactating. * medically unfit by the doctor as a result of the medical interview or physicals. * received treatment of an investigational drug within 4 weeks of study start. * currently receiving treatment with prohibited meds listed in protocol. * had major surgery in previous 2 weeks. * had prior radiation therapy to the chest to treat this incidence of breast cancer. * hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study med. * has a malabsorption syndrome.

Keywords: lapatinib breast cancer treatment-naive
study on bladder and sexual function change after simple hysterectomy

Conditions: Benign Uterine Disease

Summary: to evaluate the incidence and pattern of bladder symptoms and sexual function change occuring after simple hysterectomy and to analyze the influence of bladder symptoms and sexual function change on quality of life of patients.


Eligibility criteria:
inclusion criteria: * patients who is planed to undergo simple hysterectomy due to benign uterine disease 1. uterine leiomyoma 2. uterine adenomyosis 3. endometrial hyperplasia 4. cervical intraepithelial neoplasia (including carcinoma in situ, figo stage ia1 cancer) 5. dysfunctional uterine bleeding 6. other benign uterine disease requiring hysterectomy exclusion criteria: * patients who are taking medication for overactive bladder * patients who underwent incontinence surgery due to urinary incontinence * acute or chronic infectious disease of urinary tract * neurologic disease causing urinary abnormality * previous pelvic radiation therapy * patients who are undergoing incontinence surgery with hysterectomy * pregnant woman

Keywords: bladder symptoms sexual function quality of life simple hysterectomy
elsamitrucin (spi 28090) for relapsed or refractory non-hodgkin's lymphoma

Conditions: Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Summary: to determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-hodgkin's lymphoma (nhl). to determine if elsamitrucin is efficacious in a particular pathologic nhl subtype(s).


Eligibility criteria:
inclusion criteria: * relapsed or refractory mantle cell lymphoma and/or cll/sll except burkitt's, burkitt's like or hiv-associated lymphoma * at least one prior cytotoxic chemotherapy regimens * measurable disease * adequate bone marrow, liver and kidney function * ecog ps 0-2 exclusion criteria: * prior treatment with elsamitrucin * prior chemo, antibody or radiotherapy for nhl within 28 days prior to start to treatment * hiv positive or known aids syndrome * uncontrolled medical disease or psychiatric condition/s